FY2025 · ended Aug 31, 2025 · Revenue $0, -100.0% YoY · Filed Dec 1, 2025
Cnbx Pharmaceuticals Inc. (CNBX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Aug 31, 2025, it reported revenue of $0 and a net loss of $313,976. As of May 31, 2026 it held $9,487 in cash and investments and $120,000 in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-462,091
Operating cash flow (TTM)
$-154,169
Free cash flow
—
EPS (TTM)
$-0.00
Dividend per share
None
Shares outstanding
553.96M
+1680.6% vs prior year
Net cash
$-110,513
as of May 31, 2026
Operating margin
-448.3%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNBX (OTC)
- Fiscal year ends
- August 31
- Incorporated in
- NV
- Headquarters
- Bethesda, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1343009
- Former names
- Cannabics Pharmaceuticals Inc. (until Mar 16, 2022); American Mining Corp (until May 1, 2014); Thrust Energy Corp. (until May 10, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Aug 31, 2025 |
FY 2024 Aug 31, 2024 |
FY 2023 Aug 31, 2023 |
FY 2022 Aug 31, 2022 |
FY 2021 Aug 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $130,074 | $410,165 | — | $0 |
| Operating income | -$271,691 | -$583,139 | -$931,380 | -$3.0M | -$2.6M |
| Net income | -$313,976 | -$695,198 | -$3.7M | -$3.7M | -$3.2M |
| Diluted EPS | $0.00 | -$0.02 | -$0.42 | -$3.59 | — |
| Operating cash flow | -$171,305 | -$244,269 | -$112,521 | -$1.7M | -$2.5M |
| Total assets | $18,437 | $31,383 | $499,039 | $811,166 | $3.1M |
| Stockholders' equity | -$2.5M | -$2.5M | -$2.0M | $1.6M | $1.8M |
| Cash and investments | $15,111 | $26,416 | $129,696 | $117,515 | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Auditor change
|
Oct 1, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Jun 24, 2026 | May 31, 2026 |
| 10-Q | Quarterly report | Apr 14, 2026 | Feb 28, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 17, 2026 | Mar 10, 2026 |
| 10-Q | Quarterly report | Jan 14, 2026 | Nov 30, 2025 |
| 10-K | Annual report | Dec 1, 2025 | Aug 31, 2025 |
All 301 Cnbx Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.